A New Resource for MPN patients

MPN Cancer Connection

 

Welcome to MPN Cancer Connection, where a brighter future for MPN treatments shines on the horizon with opportunity and resources for improved patient care.

Goals

 

What Are Myeloproliferative Neoplasms?

Myeloproliferative neoplasms (MPN) are a group of diseases that affect blood-cell formation. In all forms of MPN, a bone marrow problem leads to increased levels of blood cells circulating in the bloodstream.

 
1) “Myelo” refers to bone marrow, which is the body’s blood-cell factory.
2) “Proliferative” refers to the rapid growth and production of cells.
3) “Myeloproliferative” means increased growth and production of bone marrow and blood cells.
4) “Neoplasm” means an abnormal growth of cells, especially as a characteristic of cancer.
parallax background
 

Learn More

Learn more about MPN (Myeloproliferative Neoplasms)
David Wallace, the founder of MPN-CC and PV Reporter, on location at the 2015 American Society of Hematology (ASH) conference. Carol Preston talks with David about his work providing comprehensive MPN resources to patients and his positive outlook on combination therapies. Check out the video as it provides a nice overview of present and future projects.
Ruben Mesa, M.D., Deputy Director, Mayo Clinic Cancer Center, shares an update on the latest Myeloproliferative Neoplasm research and treatment for 2016.

Like us on Facebook!

Visit our Facebook page to receive updates on MPN Cancer Connection information, events, fundraisers, stories, and resources!

Blog

September 21, 2016
hearing loss in PV

Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera

“Researchers found that the mean hemoglobin and hematocrit levels of the polycythemia vera group were 16.7 g/dL and 50.4%, respectively, vs 13.4 g/dL and 40.3% in […]
September 20, 2016
ropeginterferon

Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera

Key points The novel IFNα-2b AOP2014 administered once every two weeks (or once a month) has low toxicity and induces high and sustained response rates in […]
August 30, 2016
Understanding the JAK2 mutation

Understanding the JAK2 Mutation

THE STORY OF JAK2 Four teams race to find the mysterious cause of a group of blood cancers. Click the link below for the complete article…